CA2182024A1 - Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees - Google Patents

Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Info

Publication number
CA2182024A1
CA2182024A1 CA002182024A CA2182024A CA2182024A1 CA 2182024 A1 CA2182024 A1 CA 2182024A1 CA 002182024 A CA002182024 A CA 002182024A CA 2182024 A CA2182024 A CA 2182024A CA 2182024 A1 CA2182024 A1 CA 2182024A1
Authority
CA
Canada
Prior art keywords
preparing dry
resulting
pharmaceutical compositions
relates
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002182024A
Other languages
English (en)
Other versions
CA2182024C (fr
Inventor
Roselyne Duclos
Didier Terracol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Effik
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/FR1995/001009 external-priority patent/WO1997004749A1/fr
Publication of CA2182024A1 publication Critical patent/CA2182024A1/fr
Application granted granted Critical
Publication of CA2182024C publication Critical patent/CA2182024C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte au domaine de la chimie thérapeutique et, en particulier, à celui de la pharmacotechnie. Elle a plus particulièrement pour objet des dispersions solides d'agents médicamenteux dans un agent transporteur hydrophile, caractérisées en ce que le principe actif est dissout dans un solvant organique volatil contenant un amide cyclique très hydrophile et en ce que la solution organique est pulvérisée et séchée en un coprécipité qui est broyé, tamisé et dilué avec un excipient ou un véhicule pharmaceutiquement-acceptable. Le coprécipité sert de matière première pour la réalisation de médicaments.
CA002182024A 1995-07-27 1995-07-27 Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees Expired - Fee Related CA2182024C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1995/001009 WO1997004749A1 (fr) 1994-07-26 1995-07-27 Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Publications (2)

Publication Number Publication Date
CA2182024A1 true CA2182024A1 (fr) 1997-01-28
CA2182024C CA2182024C (fr) 2005-02-01

Family

ID=34130868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182024A Expired - Fee Related CA2182024C (fr) 1995-07-27 1995-07-27 Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Country Status (1)

Country Link
CA (1) CA2182024C (fr)

Also Published As

Publication number Publication date
CA2182024C (fr) 2005-02-01

Similar Documents

Publication Publication Date Title
US4895727A (en) Pharmaceutical vehicles for exhancing penetration and retention in the skin
US6461545B1 (en) Method of solubilizing and encapsulating itraconazole
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
US10568966B2 (en) Formulation for topical wound treatment
ATE138071T1 (de) Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
IE861813L (en) New Polysaccharide Esters and their Salts
TR200100628T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler.
WO1993017665A1 (fr) Procedes et appareils d'administration de medicaments utilisant des solutions supercritiques
TR200100569T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler
PT97638A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
BR9814818A (pt) Métodos de tratamento de cápsulas e formulações farmacêuticas em pó secas
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
GT199900069A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.
RU94022269A (ru) Состав аэрозоля, находящийся под давлением
WO2002043750A3 (fr) Procede de stabilisation de biomolecules dans des formulations liquides
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
FR2364660A1 (fr) Enrobage assurant une liberation reguliere d'ingredients actifs de compositions biologiquement actives et procede pour leur preparation
DE3601923A1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
IT1204400B (it) Composizioni farmaceutiche contenente una calcitonina
JP2001089383A (ja) 口腔用及び眼科用組成物
US5525596A (en) Absorption enhancer/solubilizer combination for improved bioavailability of a zwitterionic compound
DE69228686D1 (de) Topisch anzuwendendes arzneimittel enthaltend penciclovir
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
FR2592043A1 (fr) 2-chloro-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo-(d, g) (1, 3, 6)-dioxazocines optiquement actives, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140729